The FDA approved betibeglogene autotemcel (beti-cel; Zynteglo) for adult and pediatric patients with transfusion-dependent ...
Hosted on MSN22d
MaxCyte: Building the Future of Cell and Gene Therapy InnovationMaxCyte's technology ensures that a large number of T cells are successfully edited with CRISPR/Cas-9 molecular scissors, which is critical for the effectiveness of the therapy. Casgevy enables CRISPR ...
which is critical for the effectiveness of the therapy. Casgevy enables CRISPR/Cas-9 to edit the BCL11A gene in stem cells to produce fetal hemoglobin. The edited genes are infused into a patient ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback